Upgrade to SI Premium - Free Trial

JPMorgan Starts Seaport Therapeutics (SPTX) at Overweight

May 26, 2026 3:22 AM
JPMorgan analyst Tessa Romero initiates coverage on Seaport Therapeutics (NASDAQ: SPTX) with a Overweight rating and a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments New Coverage